GO
| HSI1 | 26,485.90 | +550.49 | 234.65B |
| HSCEI1 | 9,355.97 | +192.73 | 85.09B |
| Back Zoom + Zoom - Block Traded | |
|
2025-11-06 15:25:43 AstraZeneca PLC (AZN.US) reported a 12% increase in 3Q25 revenue to US$15.191 billion, while core EPS were US$2.38, both beating market expectations, driven by ideal sales of blockbuster cancer and diabetes drugs. Analysts initially anticipated that AstraZeneca would raise its full-year results guidance, but the Company only reiterated that full-year revenue would record high single-digit growth, with low double-digit growth in core EPS. AstraZeneca's 9M25 revenue grew by 10% to US$43.236 billion, with a core EPS of US$7.04. ~ AASTOCKS Financial News Website: www.aastocks.com | |